Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · February 23, 2017

Low-Dose Lenalidomide Is Effective and Less Toxic in Older Patients With Multiple Myeloma

British Journal of Haematology


Additional Info

Disclosure statements are available on the authors' profiles:

British Journal of Haematology
Upfront Lower Dose Lenalidomide Is Less Toxic and Does Not Compromise Efficacy for Vulnerable Patients With Relapsed Refractory Multiple Myeloma: Final Analysis of the Phase II RevLite Study
Br. J. Haematol 2017 Feb 15;[EPub Ahead of Print], H Quach, L Fernyhough, R Henderson, G Corbett, B Baker, P Browett, H Blacklock, C Forsyth, C Underhill, P Cannell, J Trotman, A Neylon, S Harrison, E Link, A Swern, L Cowan, MA Dimopoulos, HM Prince

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading